| | | | November 2022 Clinical Update: NCCN Guidelines for Treatment of Prostate Cancer
| | The National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer focus on screening, diagnosis, staging, treatment, and management. All prostate cancer therapy regimens were categorized to provide guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include comorbidities, nature of the disease, access to agents and hereditary genetic risk.
These updated guidelines include criteria for further genetic risk evaluation using a germline cancer panel for hereditary cancer syndromes: · Family history of known pathogenic variations or cancer, · Prior personal history of another type of cancer, · Tumors with certain histological characteristics and location.
The germline panels are recommended to contain the ATM, BRCA1, BRCA2, CHEK2, PALB2, MLH1, MSH2, MSH6, and PMS2 genes.
Genetics Institute of America’s GIAnomics™ Oncology Germline Panel includes all the recommended predisposition genes for breast cancer. GIA is committed to exceeding the standards put forth by prestigious organizations, like NCCN, and ensuring that the panels we offer support your medical needs and your patient’s health and safety. | | | | Have you Seen This?:
Increasing Diversity in Cancer Clinical Trials Clinical trials are vital to the development of effective drugs and therapies that increase the overall survival of cancer patients; however, very few cancer patients are able to participate, and are typically less diverse than the affected population. “Trials that are less diverse raise questions about the generalizability of results for clinical decision making and contribute to persistent racial disparities in cancer outcomes.”1 Read more >> | | | |
It's All in the Genes: Expanding Cancer Risk of BRCA1/2 Since the 1990s, BRCA1 and BRCA2 pathogenic variants have been closely associated as the causative agents of hereditary breast and ovarian cancer. As a result, genetic testing and targeted treatments have been developed in order to effectively treat and improve overall survival for these diagnoses. Read more >> | | | | Changing Corporate Culture:
Gift of Hope Toy Drive During the holiday season, the team at Genetics Institute of America will work together to bring joy and hope to our community and the families we serve. The 4KIDS Gift of Hope Annual Toy Drive presents a special opportunity to remind kids in crisis that they are not forgotten. We are helping 4KIDS collect unwrapped toys and gift cards so each foster child, teen, and young adult in their care has a present to open on Christmas Day. Read more >> | | | | | | | | Enroll your Practice in GH-101! | | Genetics Institute of America is actively recruiting practices to join our study, GH-101! The objective of this study is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics by identifying DNA and RNA variants in persons with chronic disease. We are looking for Physicians and Physician Groups that currently treat patients with a chronic disease including: cancer, cardiac conditions, diabetes, kidney disease, PTSD. Getting your practice involved is easy and not only gets patients the individualized health information they need but allows your practice to be on the cutting edge of genetic research. | | | | | | Thank you for the trust and confidence you have placed in our team here at the Genetics Institute of America. This monthly newsletter is our primary method of communicating to you important information about our testing and assays, general information about the Genetics Institute, as well as information impacting patient care and safety. If you would like to have another person in your practice receive these updates, please forward this to them so that they can subscribe.
 Ana Perez-Miranda, PhD, MDxT (AAB), MB (ASCP) Laboratory Manager and Molecular Diagnostics Supervisor Genetics Institute of America | | | | | | | | | | GIA Lab News is an educational service of Genetics Institute of America.
Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote the longevity and quality of life outcomes. Our determination and research allow us to provide next generation DNA sequencing to deliver customized testing for identified genetic related cancers and other diseases. | | | | | | 4733 W. Atlantic Ave, Suite C16 Delray Beach, FL 33445 Phone: (833) 4GENLAB or (833) 443-6522 HIPAA Fax: (561) 354-5369
| | You are receiving this email because you opted into receiving communications from Genetics Institute of America online or verbally on the phone, and/or maintain a professional relationship with our laboratory. From time to time, we’ll send newsletters, blog articles, and other educational clinical updates to our subscribers. We hope you find them useful. If not, you can unsubscribe from our list here.
Who do you know that needs to know? Forward this email Did someone forward this to you? Subscribe
Want to change how you receive these emails?
You can Unsubscribe or Update your preferences.
© 2022 Genetics Institute of America. All Rights Reserved.
| | | | | | | |
.png)
